REG - Solvonis Therapeutic - Notice of Annual General Meeting

Solvonis TherapeuticsAnnouncement

27/05/2026 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260527:nRSa8703Fa&default-theme=true

RNS Number : 8703F  Solvonis Therapeutics PLC  27 May 2026

27 May 2026
Solvonis Therapeutics plc

("Solvonis" or the "Company")

Notice of Annual General Meeting (the "AGM")

 

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company
developing novel small-molecule therapeutics for high-burden central nervous
system ("CNS") disorders, is pleased to announce that the notice of the
Company's 2026 AGM and proxy form have today been posted to shareholders and
can be found on the Company's website
at https://solvonis.com/investor-relations/shareholder-circulars
(https://solvonis.com/investor-relations/shareholder-circulars) .

The Annual General Meeting will take place at 9.00am on 19 June 2026 at the
Company's registered office being, 25 Eccleston Place, London SW1W 9NF.

In compliance with Listing Rule 9.6.1R, the notice of AGM and proxy form have
today been submitted to the National Storage Mechanism and will shortly be
available at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

Enquiries:

Solvonis Therapeutics plc

Anthony Tennyson, CEO & Executive Director

info@solvonis.com

Singer Capital Markets (Broker)

Phil Davies

+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company
developing small-molecule therapeutics for high-burden central nervous system
(CNS) disorders. Headquartered in London and listed on the main market of the
London Stock Exchange, Solvonis is advancing a differentiated pipeline of
repurposed and discovery-stage compounds across addiction and psychiatry.

The Company's lead programmes target Alcohol Use Disorder (AUD) and
Post-Traumatic Stress Disorder (PTSD), with additional development and
discovery work supporting expansion into further addiction and psychiatric
indications, including stimulant use disorder and depressive disorders.

 Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK,
while SVN-002 is preparing for a Phase 2b trial in the United States targeting
moderate-to-severe AUD. The Company's PTSD discovery programme has identified
SVN-114 as a lead compound, emerging from a proprietary compound series
designed to modulate key brain signalling systems associated with emotional
processing and social behaviour.

In parallel, Solvonis is advancing proprietary CNS discovery programmes
supported by a dedicated compound library to identify new small-molecule
modulators of key neurotransmitter systems. This platform enables efficient
early-stage innovation and supports the Company's integrated approach to
developing therapies across addiction and psychiatry.

With a capital-efficient development model and a focus on partnering
opportunities, Solvonis aims to deliver sustained value through innovation in
CNS therapeutics.

solvonis.com (https://solvonis.com/)  | LinkedIn
(https://www.linkedin.com/company/solvonis)  | X (Twitter)
(https://x.com/Solvonis)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAAKOBKFBKKCPB



            Copyright 2019 Regulatory News Service, all rights reserved